MX107 is a selective and potent survivin inhibitor that suppresses the proliferation of triple-negative breast cancer (TNBC) cells; it induces degradation of survivin and inhibitor of apoptosis proteins (IAPs), thereby inhibiting DNA damage-induced nuclear factor kappa B (NF-κB) activation; MX107 synergizes with chemotherapeutic agents to enhance the antitumor efficacy of genotoxic therapies.